NASDAQ NMS - GLOBAL MARKET · NGNE
+4.56% · +$1.57 · Vol 167.6K
After hours · updated 16:01:17 ET
Neurogene Inc

Neurogene Inc

Biotechnology
$35.98
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
NGNE
Neurogene Inc
Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is NGNE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NGNE catalysts
About Neurogene Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2023
Employees
131
Country
US

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$34.66
Day high
$36.30
Day low
$34.36
Previous close
$34.41
52W high
$42.84
-16.01% from high
52W low
$16.37
74% of range
Market cap
$686.5M
EPS
$-4.5100
Beta
1.33
Shares out
20M
Volume
167.6K
0.62× rel vol
Avg volume
271K
VWAP
$35.51
Price history computed in-house
1W
+6.89%
1M
+10.50%
3M
+15.10%
1Y
+67.74%
YTD
+74.66%
SMA 50 $32.60 · above
SMA 200 $25.27 · above
52W position 74%

NGNE overview

Veridion Score
59
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NGNE.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NGNE Form 4 filings
Public disclosures

Congress activity in NGNE

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NGNE in the cached public ledger.

Federal contracts

NGNE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NGNE in this window.
Lobbying spend

NGNE lobbying filings, year to date.

Registered lobbying filings matched to Neurogene Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NGNE in this window.
Loading news for NGNE
Analyst ratings
Sovereign unlock shows live analyst consensus for NGNE.
Options
Sovereign unlock shows live options positioning for NGNE.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.